Recombinant probiotic Lactococcus lactis delivering p62 mitigates moderate colitis in mice

Página do item simplificado
dc.creatorJuliana Guimarães Laguna
dc.creatorAndria dos Santos Freitas
dc.creatorFernanda Alvarenga Lima Barroso
dc.creatorLuís Cláudio Lima de Jesus
dc.creatorOctávio Augusto Greco Gomes de Vasconcelos
dc.creatorLudmila Silva Quaresma
dc.creatorMonique Ferrary Américo
dc.creatorGabriela Munis Campos
dc.creatorTúlio Marcos Santos
dc.creatorRafael de Assis Glória
dc.creatorJoyce da Cruz Ferraz Dutra
dc.creatorTales Fernando da Silva
dc.creatorKátia Duarte Vital
dc.creatorSimone Odília Antunes Fernandes
dc.creatorRamon de Oliveira Souza
dc.creatorFlaviano dos Santos Martins
dc.creatorEnio Ferreira
dc.creatorTúlio Marcos Santos
dc.creatorAlexander Birbrair
dc.creatorMarcos Felipe Andrade de Oliveira
dc.creatorAna Maria Caetano Faria
dc.creatorRodrigo Dias de Oliveira Carvalho
dc.creatorFranco Maria Venanzi
dc.creatorYves Le Loir
dc.creatorGwénaël Jan
dc.creatorÉric Guédon
dc.creatorVasco Ariston de Carvalho Azevedo
dc.date.accessioned2025-09-05T22:15:20Z
dc.date.accessioned2025-09-09T00:59:45Z
dc.date.available2025-09-05T22:15:20Z
dc.date.issued2024-04-03
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.format.mimetypepdf
dc.identifier.doi10.3389/fmicb.2024.1309160
dc.identifier.issn1664302X
dc.identifier.urihttps://hdl.handle.net/1843/84967
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.rightsAcesso Aberto
dc.subjectDoença inflamatória
dc.subjectProbióticos
dc.subject.otherDoença inflamatória intestinal
dc.subject.otherBactérias probióticas
dc.subject.otherProteína recombinante
dc.subject.otherImunomodulação
dc.subject.otherBarreira epitelial
dc.subject.otherMicrobiota intestinal
dc.titleRecombinant probiotic Lactococcus lactis delivering p62 mitigates moderate colitis in mice
dc.typeArtigo de periódico
local.citation.epage14
local.citation.spage1
local.citation.volume15
local.description.resumoIntroduction and objective: p62 is a human multifunctional adaptor protein involved in key cellular processes such as tissue homeostasis, inflammation, and cancer. It acts as a negative regulator of inflammasome complexes. It may thus be considered a good candidate for therapeutic use in inflammatory bowel diseases (IBD), such as colitis. Probiotics, including recombinant probiotic strains producing or delivering therapeutic biomolecules to the host mucosal surfaces, could help prevent and mitigate chronic intestinal inflammation. The objective of the present study was to combine the intrinsic immunomodulatory properties of the probiotic Lactococcus lactis NCDO2118 with its ability to deliver health-promoting molecules to enhance its protective and preventive effects in the context of ulcerative colitis (UC). Material and methods: This study was realized in vivo in which mice were supplemented with the recombinant strain. The intestinal barrier function was analyzed by monitoring permeability, secretory IgA total levels, mucin expression, and tight junction genes. Its integrity was evaluated by histological analyses. Regarding inflammation, colonic cytokine levels, myeloperoxidase (MPO), and expression of key genes were monitored. The intestinal microbiota composition was investigated using 16S rRNA Gene Sequencing. Results and discussion: No protective effect of L. lactis NCDO2118 pExu:p62 was observed regarding mice clinical parameters compared to the L. lactis NCDO2118 pExu: empty. However, the recombinant strain, expressing p62, increased the goblet cell counts, upregulated Muc2 gene expression in the colon, and downregulated pro-inflammatory cytokines Tnf and Ifng when compared to L. lactis NCDO2118 pExu: empty and inflamed groups. This recombinant strain also decreased colonic MPO activity. No difference in the intestinal microbiota was observed between all treatments. Altogether, our results show that recombinant L. lactis NCDO2118 delivering p62 protein protected the intestinal mucosa and mitigated inflammatory damages caused by dextran sodium sulfate (DSS). We thus suggest that p62 may constitute part of a therapeutic approach targeting inflammation.
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE ALIMENTOS
local.publisher.departmentFAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS
local.publisher.departmentICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA
local.publisher.departmentICB - DEPARTAMENTO DE MICROBIOLOGIA
local.publisher.departmentICB - DEPARTAMENTO DE PATOLOGIA
local.publisher.initialsUFMG
local.url.externahttps://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2024.1309160/full

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Recombinant probiotic Lactococcus lactis delivering P62 mitigates moderate colitis in mice.pdf
Tamanho:
16.95 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG